| Scientific Name |
Ofatumumab
|
|---|---|
| Brand Name |
Arzerra
|
| Risk |
Hepatitis B virus reactivation warning, Safety update on a fatal infusion reaction reported in a patient with Chronic lymphocytic leukemia (Cll) who was treated with intravenous ofatumumab, Risk of Progressive Multifocal Encephalopathy (PML) Following Ofatumumab Use.
|
| Dear Healthcare Professional Communication (DHPC) for Healthcare Professionals |
|
| Safety Communication for Healthcare Professionals |
|